Screener
Mesa Laboratories MLAB Biopharmaceutical Development — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The source filing: Mesa Laboratories’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026808
| Three months ended June 30, 2026 | Sterilization and Disinfection Control | Biopharmaceutical Development | Calibration Solutions | Clinical Genomics | Total |
|---|---|---|---|---|---|
| Amortization in cost of revenue | 121 | 379 | - | 191 | 691 |
| Other cost of revenue (b) | 6,788 | 4,020 | 5,143 | 3,739 | 19,690 |
| Total segment cost of revenue | 7,346 | 4,477 | 5,254 | 4,049 | 21,126 |
| Gross Profit (c) | $17,159 | $7,582 | $8,031 | $6,240 | $39,012 |
| Reconciling items: | |||||
| Operating expense | $31,981 | ||||
| Operating income | 7,031 | ||||
| Non-operating expense, net | 2,678 |
Document
FAQ
- What is Mesa Laboratories's biopharmaceutical development — gross profit?
- Mesa Laboratories (MLAB) reported biopharmaceutical development — gross profit of $7.58M in Q2 2026.
- How has Mesa Laboratories's biopharmaceutical development — gross profit changed year-over-year?
- Mesa Laboratories's biopharmaceutical development — gross profit increased by 20.2% year-over-year, from $6.31M to $7.58M.
- What is the long-term trend for Mesa Laboratories's biopharmaceutical development — gross profit?
- Over 4 years (2022 to 2026), Mesa Laboratories's biopharmaceutical development — gross profit has grown at a -0.0% compound annual growth rate (CAGR), from $28.61M to $28.55M.
- What does biopharmaceutical development — gross profit mean?
- Calculated as the total revenue of the Biopharmaceutical Development segment minus the total cost of revenue. This metric measures the profitability of the segment's core production and service delivery before accounting for operating expenses like R&D, sales, or administration. It indicates the segment's ability to manage production costs and maintain pricing power.
Ask your AI about Mesa Laboratories's biopharmaceutical development — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude